Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen (LIRA-B)
This study has been completed.
Information provided by (Responsible Party):
First received: September 16, 2010
Last updated: September 23, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||September 23, 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Chan HL, Ahn SH, Chang TT, Peng CY, Wong D, Coffin CS, Lim SG, Chen PJ, Janssen HL, Marcellin P, Serfaty L, Zeuzem S, Cohen D, Critelli L, Xu D, Wind-Rotolo M, Cooney E; LIRA-B Study Team.. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J Hepatol. 2016 May;64(5):1011-9. doi: 10.1016/j.jhep.2015.12.018. Epub 2015 Dec 29.